Carbon C 14 ibcasertib

{
  "id": "MLC-T-ONC-012275",
  "term": "Carbon C 14 ibcasertib",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable radioconjugate composed of ibcasertib, an orally bioavailable inhibitor of select serine-threonine kinases including aurora kinase B (aurora B), vascular endothelial growth factor receptors (VEGFRs), stem cell factor receptor (c-KIT) and platelet-derived growth factor receptors (PDGFRs), radiolabeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of chiauranib. Upon oral administration of carbon C 14 ibcasertib, ibcasertib targets, binds to and inhibits the activity of aurora B, VEGFRs, c-kit and PDGFRs, which may result in a decrease in the proliferation of tumor cells that overexpress these kinases. Labeling of ibcasertib with the radioactive tracer carbon C 14 allows for the evaluation of chiauranib's pharmacokinetic profile, including its absorption, distribution, metabolism and excretion (ADME).",
  "synonyms": [
    "[14C]-chiauranib",
    "[14C]chiauranib",
    "[14C]-CS2164",
    "[14C]-cioroni",
    "14C-ibcasertib",
    "carbon C 14 chiauranib"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/carbon-c-14-ibcasertib/"
}